Format

Send to

Choose Destination
J Cell Mol Med. 2016 Mar;20(3):559-67. doi: 10.1111/jcmm.12760. Epub 2016 Jan 22.

miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells.

Author information

1
The State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan, China.
2
The Clinical Laboratory of No.261 Hospital of the People's Liberation Army, Beijing, China.

Abstract

Increased miR-222 levels are associated with a poor prognosis in patients with bladder cancer. However, the role of miR-222 remains unclear. In the present study, we found that miR-222 enhanced the proliferation of both the T24 and the 5637 bladder cancer cell lines. Overexpression of miR-222 attenuated cisplatin-induced cell death in bladder cancer cells. miR-222 activated the Akt/mTOR pathway and inhibited cisplatin-induced autophagy in bladder cancer cells by directly targeting protein phosphatase 2A subunit B (PPP2R2A). Blocking the activation of Akt with LY294002 or mTOR with rapamycin significantly prevented miR-222-induced proliferation and restored the sensitivity of bladder cancer cells to cisplatin. These findings demonstrate that miR-222 modulates the PPP2R2A/Akt/mTOR axis and thus plays a critical role in regulating proliferation and chemotherapeutic drug resistance. Therefore, miR-222 may be a novel therapeutic target for bladder cancer.

KEYWORDS:

bladder cancer; cisplatin; microRNA-222

PMID:
26800397
PMCID:
PMC4759461
DOI:
10.1111/jcmm.12760
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center